<a href="https://www.fiercebiotech.com/biotech/blackstone-invests-250m-anagram-reduce-burden-cf-complication" hreflang="en">Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication</a>
Blackstone Life Sciences has invested $250 million in Anagram Therapeutics to develop ANG003, an oral enzyme replacement therapy aimed at reducing the pill burden for cystic fibrosis patients with exocrine pancreatic insufficiency from up to 40 pills a day to just three. This funding follows prior support from the Cystic Fibrosis Foundation and is part of Anagram's efforts to improve treatment options for patients suffering from this condition.
Blackstone's $250 million investment in Anagram Therapeutics to develop ANG003, a recombinant enzyme replacement therapy for exocrine pancreatic insufficiency in cystic fibrosis patients, signals a significant opportunity in reducing treatment burdens and addressing current limitations of PERT derived from pig pancreas glands. This move highlights the potential for innovative biotech solutions to transform treatment paradigms, offering a strategic investment opportunity with implications for future FDA approvals and market adoption in the healthtech sector.